RNA Formulation Resources

  1. Genome Editing Using mRNA-Lipid Nanoparticles For CAR T Cell Therapy 11/22/2023

    Gene delivery platforms must support a diversity of genetic engineering strategies for genomic medicine development. Learn how lipid nanoparticles can accelerate development from discovery to scale-up.

  2. Lipid Nanoparticle Library For Non-Viral Delivery Of mRNA And saRNA Towards Vaccine And Cell & Gene Therapy Applications 4/18/2022

    Explore this proprietary ionizable lipid library which has shown promising potency towards various applications involving cell therapy, protein replacement therapy and RNA-based Vaccines.

  3. Linear Scalability In Turbulent‐Jet Mixing For Nanoparticle Processing 10/14/2025

    Understand how turbulent-jet mixing ensures predictable and reproducible nanoparticle size and uniformity across all scales, accelerating development and regulatory readiness.

  4. Scale-Up And Manufacturing Of Self-Amplifying RNA-LNPs 4/18/2022

    This poster shows the work to scale up COVID-19 self-amplifying RNA-Lipid nanoparticle using PNI developed ionizable lipid and formulation from 0.2, to 50 mg scale using PNI’s Manufacturing Platform.

  5. Optimizing Lipid Formulations For Targeted RNA-LNP Applications 9/13/2022

    Learn about the considerations and challenges of using ionizable lipids, including the 5 types of lipids used for RNA delivery.

  6. Drug Discovery And Screening, A Digital Era For RNA-LNP Therapeutics 11/21/2022

    Learn about the key stages of drug discovery and screening as well as how to overcome bottlenecks in screening mRNA-LNPs to rapidly develop genomic medicines.

  7. Strategies To Overcome Delays In The Development Of Genomic Medicines 10/13/2022

    Learn how optimizing LNPs can help overcome drug-delivery challenges, unlocking potential new genomic medicines in a shorter time.

  8. Navigating Challenges In Progressing Breakthrough RNA Therapeutics 5/14/2024

    RNA therapeutics hold immense promise for precision treatment, but their development faces challenges. A CDMO with adaptable platforms and flexible timelines can help reduce time and costs.

  9. Process Development Considerations For RNA-LNP Therapeutics 9/13/2022

    Here, we highlight three important process considerations across the RNA-LNP manufacturing workflow which includes limit size behavior, in-line dilution and downstream tangential flow filtration (TFF).

  10. Gene Therapy And Oligonucleotide Compendium 1/25/2022

    Technical summaries and detailed protocols for purity testing, sizing, sequencing and expression analysis of oligonucleotide-based active agents as well as protein and lipid-based delivery systems.